This is the clinically honest guide to the best medical weight loss programs in 2026 — what they actually cost, how GLP-1 supervision really works, and why the business model of your provider determines your clinical outcome more than almost anything else.
- FDA-approved branded GLP-1 medications (Wegovy, Zepbound) are the current standard of care for clinically supervised medical weight loss. Compounded semaglutide and tirzepatide are now FDA-restricted following the resolution of the national drug shortage.
- The business model of your weight loss provider determines your clinical outcome. A provider that makes margin on medication has a structural incentive to keep you on the highest dose indefinitely. GoodLife Health makes no margin on any medication, ever.
- Unsupervised GLP-1 use without baseline labs, ongoing titration, and a maintenance protocol produces predictable clinical harm: significant lean muscle mass loss, weight regain within 12 months of discontinuation, and unmanaged side effects that cause premature dropout.
- GoodLife Health at $399 per month covers the full clinical relationship: baseline metabolic panel, protocol design, ongoing titration, side effect management, hormone assessment, and maintenance planning. The medication is paid separately through your pharmacy, with or without insurance.
- For most patients on bronze or marketplace health plans with individual deductibles above $1,800, the total annual cost of GoodLife membership is equal to or less than what they spend hitting their deductible, with meaningfully more clinical contact and a structured protocol.
- GoodLife Health operates across all 50 states through board-certified clinicians under the medical direction of Kristin Makinajyan, DNP, FNP-BC. Every protocol is designed by a named clinician who has reviewed your labs. No algorithm prescribes here.
You Walked In With a List of Symptoms. You Walked Out With Nothing.
You have probably been here before. You scheduled the appointment, prepared your questions, described your symptoms clearly, and waited six weeks for a slot with a clinician you would see for eleven minutes. You walked out with a referral you never used, a lab result described as "within normal limits," and the quiet suspicion that the system was not designed to actually solve your problem.
That experience is not unique to you. It is the defining experience of primary care in the United States in 2026. The average primary care appointment lasts 18 minutes, of which approximately 5 minutes involves direct clinician conversation. The remaining time is documentation. For patients navigating weight gain, hormonal symptoms, metabolic dysfunction, or the slow accumulation of conditions that do not yet have a clean diagnostic code, that 5 minutes is not enough. It has never been enough.
Medical weight loss is the clearest example of this failure. Obesity is a chronic, complex, multifactorial disease with well-documented hormonal, metabolic, genetic, and behavioral components. It is not a willpower deficit. The clinical literature has been clear on this for two decades. And yet the standard insurance-based primary care response to a patient presenting with obesity, fatigue, insulin resistance, and low thyroid function is often a brief conversation about diet and exercise, a referral to a nutritionist, and a follow-up in three months.
The GLP-1 revolution changed what is possible. Medications like semaglutide (Wegovy) and tirzepatide (Zepbound) produce clinically meaningful weight loss in the majority of patients who use them correctly, inside a supervised protocol, with baseline labs, ongoing titration, and a maintenance plan designed from the beginning. The operative phrase is "correctly, inside a supervised protocol." That is the part the compounded telehealth market sold you on and then failed to deliver. And that is the gap GoodLife Health was built to close.
What Medical Weight Loss Actually Means in 2026
Medical weight loss is not a diet program with a clinician's signature on it. It is a clinical discipline that treats excess body weight as a chronic disease requiring the same longitudinal management as hypertension, diabetes, or thyroid dysfunction. The distinction matters because it determines everything downstream: which interventions are appropriate, how they are monitored, how long they are maintained, and what happens when they stop working or need adjustment.
In clinical practice, a properly structured medical weight loss protocol begins with a comprehensive metabolic panel. This is not optional. GLP-1 medications interact with thyroid function, kidney function, lipid metabolism, insulin sensitivity, and liver enzymes. A clinician who prescribes without reviewing these markers is not practicing medicine. They are dispensing a product.
The second component is protocol design: a starting dose calibrated to the individual patient's weight, metabolic markers, and prior medication history, with dose escalation criteria, side effect thresholds, and check-in intervals. It means assessing hormonal status, because thyroid dysfunction and sex hormone imbalance are among the most common contributors to weight loss resistance.
The third component is ongoing titration and monitoring. GLP-1 therapy is not a set-and-forget prescription. Doses are adjusted based on response, tolerance, and lab trends. Side effects require clinical management, not a support chat bot.
The fourth and most commonly omitted component is maintenance protocol design. The STEP 4 trial documented that patients who discontinued semaglutide without a maintenance protocol regained approximately two-thirds of their lost weight within one year. The drug works while you take it. The protocol determines whether the outcome is permanent.
The drug works while you take it. The protocol determines whether the outcome is permanent.
The GLP-1 Landscape in 2026: What Changed and Why It Matters
Between 2021 and 2024, compounded versions of semaglutide and tirzepatide were legally available through licensed compounding pharmacies because both drugs appeared on the FDA's drug shortage list. Many patients accessed medication through this pathway and had meaningful outcomes. They were not wrong to do so. The regulatory environment permitted it.
In 2025, the FDA determined that the shortage of both semaglutide and tirzepatide had been resolved. Under federal law, once a shortage is resolved, the legal basis for compounding that drug is removed for most compounding pharmacies. Compounded semaglutide and tirzepatide are now restricted for most patients and most providers.
This is not a moral judgment about patients who used compounded GLP-1. It is a statement of regulatory fact. The ground shifted. The current standard of care is FDA-approved branded medication: semaglutide as Wegovy or Ozempic, and tirzepatide as Zepbound or Mounjaro. GoodLife Health has prescribed exclusively FDA-approved branded GLP-1 medications from our founding.
The Muscle Loss Problem Nobody in the Compounded Market Told You About
GLP-1 medications produce weight loss through appetite suppression, slowed gastric emptying, and improved insulin signaling. The SURMOUNT-1 trial showed that tirzepatide produced average weight loss of 20.9 percent of body weight at the highest dose over 72 weeks. The STEP-1 trial showed semaglutide producing average weight loss of 14.9 percent over 68 weeks.
What the headline numbers do not show is body composition. When patients lose weight rapidly without adequate protein targets, resistance exercise guidance, and dose titration, a meaningful portion of the loss is lean muscle mass. This is called GLP-1-associated sarcopenia, and it is a predictable consequence of unsupervised rapid weight loss rather than a side effect of the medication itself.
Muscle is metabolically active tissue responsible for a substantial portion of resting metabolic rate. A patient who loses 30 pounds but loses 8 to 10 of those as lean mass exits therapy with a lower resting metabolic rate than when they started — and regains weight faster, with a higher relative body fat percentage, if they discontinue without a maintenance protocol.
The consequences are long-lasting. Muscle is metabolically active tissue responsible for a substantial portion of resting metabolic rate. A patient who loses 30 pounds but loses 8 to 10 of those as lean mass exits therapy with a lower resting metabolic rate than when they started. If they discontinue without a maintenance protocol, they regain weight faster, with a higher relative body fat percentage. The supervised protocol that prevents this requires a clinician actively monitoring it: baseline body composition, protein targets, resistance exercise guidance, dose titration designed to preserve muscle, and regular reassessment. This is what GoodLife Health delivers as part of every Tier 2 membership.
The Business Model Is the Clinical Outcome
Every business in the medical weight loss market makes money in one of two ways. It makes money on the clinical relationship, or it makes money on the drug. These are not equally aligned with patient outcomes.
A platform that makes money on drug volume — through prescription fees, medication markups, compounding margins, or refill incentives — has a structural financial incentive to keep you on the drug at the highest tolerable dose for as long as possible. It does not mean every individual clinician acts in bad faith. It means the incentive structure of the organization is pointed at your refill, not your outcome.
MEDVi is the most prominent example of this model. MEDVi built a patient acquisition machine around compounded semaglutide and tirzepatide, with medication bundled into a subscription that made the clinical relationship inseparable from the drug revenue. When the FDA restricted compounded GLP-1, the business model was exposed. We are not making this argument to shame patients who used MEDVi. We are making it because understanding the structure of these businesses is the only way to evaluate them honestly.
GoodLife Health is structured differently at the foundational level. Our revenue comes from your membership. We make no margin on any medication. We do not own a pharmacy. We do not have a compounding relationship. We do not take referral fees from any drug manufacturer or pharmacy benefit manager. The prescription follows the clinical assessment. The clinical assessment is never designed around a prescription. Our revenue depends on your outcome. You stay when you get results. That is not a promise — it is an incentive structure, and it is the only one in this market that is structurally on your side.
Where the money comes from
Two business models in medical weight loss
| Model | Revenue Source | Medication Margin |
|---|---|---|
| Compounded/subscription-bundled platforms (e.g., MEDVi) | Prescription fees, medication markups, compounding margins, refill incentives | Built into the monthly subscription |
| GoodLife Health | Membership fee for the clinical relationship only | None — medication is paid separately at your pharmacy |
What $399 Per Month Actually Buys You
The first objection every patient raises is cost. It is the right objection to raise. So here is exactly what $399 per month buys you inside GoodLife Health Tier 2, and what it does not.
What it covers is the full clinical relationship for medical weight loss combined with hormone optimization: a comprehensive metabolic panel before your protocol begins, a named board-certified clinician designing a protocol specific to your biology, ongoing titration of your GLP-1 based on your response and lab trends, hormone assessment as a standard component, unlimited secure messaging, monthly check-ins, and a maintenance protocol designed from your first appointment.
What it does not cover is the medication itself. Your GLP-1 prescription, whether Wegovy or Zepbound, is filled at a standard licensed pharmacy and paid separately. This is by design. Bundling medication into a membership fee is how platforms obscure their drug margin. We do not obscure ours because we do not have one. You see every line.
For the patient who has spent two years cycling through compounded GLP-1 at $200 to $400 per month without a supervising clinician, the cost of that cycle has likely exceeded $5,000 with limited durable outcome. One year of GoodLife at $399 per month is $4,788, with a structured protocol, clinical supervision, hormone assessment, and a maintenance plan designed to make the result permanent. The comparison is not $399 per month versus cheaper. It is $399 per month versus the total cost of doing it wrong repeatedly.
For the patient carrying a marketplace bronze plan with an individual deductible of $3,000 to $7,500: you are paying that deductible before insurance covers a single dollar of primary care, and hormone optimization, comprehensive functional labs, and GLP-1 for weight management are routinely excluded or denied. GoodLife at $399 per month covers all three. The financially sophisticated move is to pair GoodLife with a high-deductible health plan and pay less in total than you paid for a PPO that gave you eleven-minute appointments after a six-week wait.
Prior Authorization: What We Will Do and What We Will Not Promise
Wegovy lists at approximately $1,350 per month without insurance. Zepbound lists at approximately $1,060 per month without insurance. These are real costs that deserve a real answer.
GoodLife Health will always pursue prior authorization for branded GLP-1 medications where your insurance plan provides a pathway. We build the clinical documentation, provide supporting lab data, and submit on your behalf. We will resubmit on denial when the clinical record supports appeal.
We will also not promise you that prior authorization will succeed. Medicare Part D covers Wegovy for patients with established cardiovascular disease following the SELECT trial, which showed a 20 percent reduction in major adverse cardiovascular events. Medicare does not cover Wegovy for weight loss alone. Commercial coverage depends on your specific plan. Where prior authorization is denied, we help you access manufacturer savings programs including the Wegovy savings card from Novo Nordisk and the Zepbound savings card from Eli Lilly. What we will never do is substitute a compounded version to reduce your cost.
The GoodLife Health Protocol
Kristin Makinajyan, DNP, FNP-BC, our Co-Founder and Chief Medical Officer, has spent 25 years in patient care across trauma ICU, home health, primary care, and integrative medicine. Her clinical philosophy is grounded in a principle that should be obvious but is rarely practiced: you cannot design a weight loss protocol without understanding the patient's hormonal environment.
Weight loss resistance is frequently not a caloric problem. It is a thyroid problem, an estrogen problem, a testosterone problem, an insulin resistance problem, or some combination. A patient whose TSH is running high-normal, whose free T3 is suboptimal, and whose insulin sensitivity is impaired will not lose weight effectively on GLP-1 regardless of dose.
Weight loss resistance is frequently not a caloric problem. It is a thyroid problem, an estrogen problem, a testosterone problem, an insulin resistance problem, or some combination. A patient whose TSH is running high-normal, whose free T3 is suboptimal, and whose insulin sensitivity is impaired will not lose weight effectively on GLP-1 regardless of dose. Every GoodLife Tier 2 protocol begins with a comprehensive lab panel — thyroid markers beyond TSH alone, sex hormone levels, metabolic markers, lipids, kidney and liver function, and insulin sensitivity indicators — and the protocol follows the labs, not a default template.
This telehealth infrastructure, designed by our Co-Founder and CEO Dev Chatterjee and powered by Cassandra, our AI-native clinical workflow platform, is what lets our clinicians practice this way at scale across all 50 states. Cassandra supports Kristin: she surfaces lab trends, organizes intake, and structures workflows. She does not diagnose. She does not prescribe. She gives the clinician more of the thing patients deserve most: attention.
Frequently Asked Questions
What is the difference between GoodLife Health and MEDVi for medical weight loss?
GoodLife Health charges a membership fee for the clinical relationship only and makes no margin on any medication. MEDVi bundled compounded semaglutide and tirzepatide into its subscription model, generating revenue from medication volume. Compounded GLP-1 medications are now FDA-restricted following the resolution of the drug shortage. GoodLife Health prescribes exclusively FDA-approved branded medications including Wegovy and Zepbound, requires comprehensive baseline labs before any protocol begins, and assigns a named board-certified clinician to every patient.
What does GoodLife Health Tier 2 at $399 per month include?
GoodLife Health Tier 2 covers the full clinical relationship for medical weight loss combined with hormone optimization. This includes a comprehensive baseline metabolic panel, protocol design by a named board-certified clinician, ongoing GLP-1 titration, hormone assessment, unlimited secure messaging, monthly check-ins, and a maintenance protocol designed from enrollment. The GLP-1 medication itself is paid separately at your pharmacy. GoodLife takes no margin on any prescription.
Why is compounded semaglutide now restricted?
Compounded semaglutide and tirzepatide were legally
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). 2021. pubmed.ncbi.nlm.nih.gov/33755728/
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). 2023. pubmed.ncbi.nlm.nih.gov/37952131/